DeepMed Research

Carotuximab

Generic Name: Carotuximab

Drug Type: Biotech

CAS Number: 1268714-50-6

Unique Ingredient Identifier: YB2EWE6139

Indication: Investigated for use/treatment in solid tumors.

Clinical Trials

Study of Apalutamide with Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

Phase 2

Recruiting

Conditions: Castration-resistant Prostate Cancer

Interventions: Drug: Apalutamide
Drug: Carotuximab

First Posted Date: 2022-09-09

Last Posted Date: 2025-02-05

Lead Sponsor: Edwin Posadas, MD

Target Recruit Count: 100

Registration Number: NCT05534646

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Huntsman Cancer Institute and Hospital, Salt Lake City, Utah, United States

Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Non Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Osimertinib
Drug: Carotuximab

First Posted Date: 2022-06-02

Last Posted Date: 2025-03-05

Lead Sponsor: Karen Reckamp, MD, MS

Target Recruit Count: 60

Registration Number: NCT05401110

Locations: 🇺🇸
Cedars-Sinai Cancer at The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC, Torrance, California, United States
🇺🇸
Cedars-Sinai Cancer at Beverly Hills (THO), Beverly Hills, California, United States

and more 2 locations

Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: TRC105

First Posted Date: 2018-12-19

Last Posted Date: 2019-10-28

Lead Sponsor: Tracon Pharmaceuticals Inc.

Target Recruit Count: 15

Registration Number: NCT03780010

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: TRC105
Drug: Abiraterone
Drug: Enzalutamide

First Posted Date: 2018-02-01

Last Posted Date: 2020-12-30

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 11

Registration Number: NCT03418324

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Carotuximab (TRC105)
Drug: OPDIVO

First Posted Date: 2017-06-08

Last Posted Date: 2020-06-24

Lead Sponsor: Tracon Pharmaceuticals Inc.

Target Recruit Count: 11

Registration Number: NCT03181308

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Phase 2

Terminated

Conditions: Gestational Trophoblastic Neoplasia
Choriocarcinoma
Placental Site Trophoblastic Tumor
Epithelioid Trophoblastic Tumor

Interventions: Drug: TRC105
Drug: Bevacizumab

First Posted Date: 2016-01-27

Last Posted Date: 2019-07-23

Lead Sponsor: Tracon Pharmaceuticals Inc.

Target Recruit Count: 3

Registration Number: NCT02664961

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
UT Southwestern, Dallas, Texas, United States

Trial of TRC105 and Sorafenib in Patients With HCC

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Carotuximab (TRC105)
Drug: Sorafenib

First Posted Date: 2015-09-25

Last Posted Date: 2020-07-17

Lead Sponsor: Tracon Pharmaceuticals Inc.

Target Recruit Count: 27

Registration Number: NCT02560779

Locations: 🇺🇸
University Hospitals, Cleveland, Ohio, United States
🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Letrozole
Drug: Everolimus
Drug: TRC105

First Posted Date: 2015-08-11

Last Posted Date: 2024-12-27

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 15

Registration Number: NCT02520063

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: TRC105

First Posted Date: 2015-04-29

Last Posted Date: 2021-06-28

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 16

Registration Number: NCT02429843

Locations: 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Conditions: Solid Tumors

First Posted Date: 2015-02-03

Last Posted Date: 2021-02-15

Lead Sponsor: Tracon Pharmaceuticals Inc.

Registration Number: NCT02354612

Locations: 🇺🇸
UCLA, Santa Monica, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy